A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores

European Journal of Pharmaceutical Sciences

Volumn 109, Issue , 2017, Pages S154-S160

  Korell, Julia ^a   Green, Bruce ^a   DeVincenzo, John ^b   Huntjens, Dymphy ^c  

^a Model Answers Pty Ltd   (Australia)

^b LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antivirals; Modelling and simulation; NONMEM; Pharmacodynamics; Pharmacometrics; Respiratory syncytial virus

Indexed keywords

ANTIVIRUS AGENT; JNJ 53718678; PLACEBO; UNCLASSIFIED DRUG; IMIDAZOLIDINE DERIVATIVE; INDOLE DERIVATIVE; JNJ-53718678;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ELIMINATION RATE CONSTANT; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INCUBATION TIME; INFECTION RATE; INFLUENZA A; KINETICS; LIMIT OF QUANTITATION; LOWER RESPIRATORY TRACT INFECTION; MALE; MEAN TRANSIT TIME; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NASAL LAVAGE; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL MODEL; STRUCTURAL MODEL; SYMPTOM; TARGET CELL; VIRAL CLEARANCE; VIRION; VIRUS INACTIVATION; VIRUS LOAD; ADOLESCENT; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; VIROLOGY; VIRUS REPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HUMANS; IMIDAZOLIDINES; INDOLES; KINETICS; MALE; NASAL LAVAGE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; VIRUS REPLICATION; YOUNG ADULT;

EID: 85020824393     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2017.05.070     Document Type: Article

References (29)

1. Ackermann, M., Alnajjar, S., Larios-Mora, A., Koul, A., Rigaux, P., Gallup, J., Huntjens, D., Roymans, D., Sitthicharoenchai, P., Therapeutic efficacy of jnj-53718678, a RSV fusion inhibitor, in neonatal lambs. 10th International Respiratory Syncytial Virus Symposium, Patagonia, 2016.
2. Baccam, P., Beauchemin, C., Macken, C.A., Hayden, F.G., Perelson, A.S., Kinetics of influenza A virus infection in humans. J. Virol. 80:15 (2006), 7590–7599.
3. Beal, S.L., Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:5 (2001), 481–504 Oct.
4. Centers for Disease Control and Prevention. Respiratory Syncytial Virus (RSV) Season, U.S., 2011-2012. 2012 Available on http://www.cdc.gov/Features/dsRSV/ Accessed on 14 April 2014.
5. Colman, P.M., Lawrence, M.C., The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4:4 (2003), 309–319.
6. DeVincenzo, J.P., El Saleeby, C.M., Bush, A.J., Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis. 191:11 (2005), 1861–1868.
7. DeVincenzo, J.P., Wilkinson, T., Vaishnaw, A., Cehelsky, J., Meyers, R., Nochur, S., Harrison, L., Meeking, P., Mann, A., Moane, E. et al., Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 182:10 (2010), 1305–1314.
8. DeVincenzo, J.P., McClure, M.W., Symons, J.A., Fathi, H., Westland, C., Chanda, S., Lambkin-Williams, R., Smith, P., Zhang, Q., Beigelman, L., Blatt, L.M., Fry, J., Activity of oral als-008176 in a respiratory syncytial virus challenge study. N. Engl. J. Med. 373:21 (2015), 2048–2058 Nov.
9. El Saleeby, C.M., Bush, A.J., Harrison, L.M., Aitken, J.A., DeVincenzo, J.P., Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J. Infect. Dis. 204:7 (2011), 996–1002.
10. Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:17 (2005), 1749–1759.
11. Feltes, T.F., Sondheimer, H.M., Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin. Biol. Ther. 7:9 (2007), 1471–1480.
12. Handel, A., Brown, J., Stallknecht, D., Rohani, P., A multi-scale analysis of influenza A virus fitness trade-offs due to temperature-dependent virus persistence. PLoS Comput. Biol. 9:3 (2013), 1–13.
13. Israel, S., Rusch, S., DeVincenzo, J., Boyers, A., Fok-Seang, J., Huntjens, D., Lounis, N., Marin, K., Stevens, M., Verloes, R., Effect of Oral jnj-53718678 (jnj-678) on Disease Severity in Healthy Adult Volunteers Experimentally Inoculated with Live Respiratory Syncytial Virus (RSV): A Placebo-controlled Challenge Study. IDweek. 2016.
14. Kielian, M., Rey, F.A., Virus membrane-fusion proteins: more than one way to make a hairpin. Nat. Rev. Microbiol. 4:1 (2006), 67–76.
15. Menache, M.G., Hanna, L.M., Gross, E.A., Lou, S.R., Zinreich, S.J., Leopold, D.A., Jarabek, A.M., Miller, F.J., Upper respiratory tract surface areas and volumes of laboratory animals and humans: considerations for dosimetry models. J. Toxicol. Environ. Health 50 (1997), 475–506.
16. Mesa, H., Bleakley, K., Lavielle, M., Improved Diagnostic Plots Require Improved Statistical Tools. Implementation in MONOLIX 4.0. 2011 Abstract 2180, http://http://www.page-meeting.org/?abstract=2180.
17. Miao, H., Xia, X., Perelson, A.S., Wu, H., On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Rev. Soc. Ind. Appl. Math. 53:1 (2011), 3–39.
18. Milligan, P.A., Marshall, S.F., Karlsson, M.O., A population pharmacokinetic and pharmacodynamic analysis of sildenafil phase III data. Population Approach Group Europe (PAGE) Abstract 136, 1999.
19. Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., O'Brien, K.L., Roca, A., Wright, P.F., Bruce, N. et al., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:9725 (2010), 1545–1555.
20. Roymans, D., Rigaux, P., Kwanten, L., Vandesteene, C., Van Ginderen, M., Van den Berg, J., Verheyen, N., McLellan, J., Battles, M., Langedijk, J., Vendeville, S., Raboisson, P., Simmen, K., Koul, A., Discovery of JNJ-53718678, a potent inhibitor of RSV. 9th International Respiratory Syncytial Virus Symposium, Cape Town, 2014.
21. Rudan, I., Boschi-Pinto, C., Biloglav, Z., Mulholland, K., Campbell, H., Epidemiology and etiology of childhood pneumonia. Bull. World Health Organ. 86:5 (2008), 408–416B.
22. Saravolatz, L.D., Empey, K.M., Peebles, R.S., Kolls, J.K., Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50:9 (2010), 1258–1267.
23. Smith, A.M., Perselson, A.S., Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:4 (2011), 429–445.
24. Stafford, M.A., Corey, L., Cao, Y., Darr, E.S., Ho, D.D., Perelson, A.S., Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 203 (2000), 285–301.
25. Stevens, M., Human proof of antiviral therapeutic activity for the oral fusion inhibitor, jnj-53718678. 10th International Respiratory Syncytial Virus Symposium, 2016.
26. Stram, D.O., Kee, J.K.W., Variance components testing in the longitudinal mixed effects model. Biometrics, 1994, 1171–1177.
27. Wahlby, U., Bouw, M.R., Jonsson, E.N., Karlsson, M.O., Assessment of type I error rates for the statistical sub-model in NONMEM. J. Pharmacokinet. Pharmacodyn. 29:3 (2002), 251–269.
28. Wainwright, C., Acute viral bronchiolitis in children - a very common condition with few therapeutic options. Paediatr. Respir. Rev. 11:1 (2010), 39–45.
29. Zhang, L., Beal, S.L., Sheiner, L.B., Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J. Pharmacokinet. Pharmacodyn. 30:6 (2003), 387–404 Dec.